(PTGX) Protagonist Therapeutics - Ratings and Ratios
Inject, Hepcidin, Mimetic, Blockers, Integrin
PTGX EPS (Earnings per Share)
PTGX Revenue
Description: PTGX Protagonist Therapeutics August 03, 2025
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company focused on developing innovative peptide therapeutics for treating hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. The companys pipeline includes several promising candidates, such as Rusfertide, Icotrokinra, and PN-943, which are in various stages of clinical trials.
Key pipeline assets include Rusfertide, a hepcidin mimetic in Phase 3 trials for polycythemia vera, and Icotrokinra, an oral investigational drug in Phase 3 trials targeting pathways currently addressed by injectable antibody drugs. PN-943, an oral alpha4 beta7 specific integrin antagonist, has completed Phase 2 trials in moderate to severe ulcerative colitis. Other assets in development include IL-17 oral peptide antagonist PN-88 and an oral hepcidin mimetic/ferroportin blocker in pre-clinical stages.
From a financial perspective, PTGX has a market capitalization of approximately $3.385 billion USD, with a forward P/E ratio of 26.39, indicating potential for growth. The companys Return on Equity (RoE) stands at 9.22%, suggesting a relatively stable financial position. To further evaluate PTGXs potential, we can examine additional KPIs such as revenue growth, R&D expenses as a percentage of revenue, and cash reserves. A review of these metrics can provide insight into the companys ability to fund its pipeline and drive future growth.
Some key performance indicators (KPIs) to monitor for PTGX include: 1. Cash and cash equivalents to track the companys ability to fund its operations and clinical trials. 2. Research and Development (R&D) expenses as a percentage of revenue to assess the companys commitment to innovation. 3. Pipeline progress, including updates on ongoing clinical trials and potential FDA approvals. 4. Revenue growth, which could be driven by future commercial sales of its pipeline assets. By closely monitoring these KPIs, investors can gain a better understanding of PTGXs potential for long-term success.
PTGX Stock Overview
| Market Cap in USD | 4,759m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-08-11 |
PTGX Stock Ratings
| Growth Rating | 84.7% |
| Fundamental | 52.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 42.7% |
| Analyst Rating | 4.40 of 5 |
PTGX Dividends
Currently no dividends paidPTGX Growth Ratios
| Growth Correlation 3m | 94% |
| Growth Correlation 12m | 85.3% |
| Growth Correlation 5y | 46.1% |
| CAGR 5y | 117.73% |
| CAGR/Max DD 3y (Calmar Ratio) | 2.26 |
| CAGR/Mean DD 3y (Pain Ratio) | 8.17 |
| Sharpe Ratio 12m | 0.26 |
| Alpha | 27.34 |
| Beta | 2.202 |
| Volatility | 52.25% |
| Current Volume | 623k |
| Average Volume 20d | 938.4k |
| Stop Loss | 74.8 (-4%) |
| Signal | 0.89 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (52.0m TTM) > 0 and > 6% of Revenue (6% = 12.6m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -32.39pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 271.1% (prev 165.9%; Δ 105.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 39.5m <= Net Income 52.0m (YES >=105%, WARN >=100%) |
| Net Debt (-157.3m) to EBITDA (25.4m) ratio: -6.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 16.97 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.5m) change vs 12m ago 3.60% (target <= -2.0% for YES) |
| Gross Margin 99.71% (prev 98.94%; Δ 0.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.39% (prev 51.92%; Δ -20.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.80 (EBITDA TTM 25.4m / Interest Expense TTM -29.8m) >= 6 (WARN >= 3) |
Altman Z'' -4.46
| (A) 0.79 = (Total Current Assets 602.5m - Total Current Liabilities 35.5m) / Total Assets 718.0m |
| (B) -0.54 = Retained Earnings (Balance) -386.9m / Total Assets 718.0m |
| (C) 0.04 = EBIT TTM 24.0m / Avg Total Assets 666.3m |
| (D) -7.74 = Book Value of Equity -387.0m / Total Liabilities 50.0m |
| Total Rating: -4.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.04
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 0.88% = 0.44 |
| 3. FCF Margin 17.74% = 4.43 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -6.19 = 2.50 |
| 6. ROIC - WACC (= -10.39)% = -12.50 |
| 7. RoE 8.12% = 0.68 |
| 8. Rev. Trend 64.36% = 4.83 |
| 9. EPS Trend 23.23% = 1.16 |
What is the price of PTGX shares?
Over the past week, the price has changed by +1.55%, over one month by +21.42%, over three months by +44.49% and over the past year by +69.67%.
Is Protagonist Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PTGX is around 86.59 USD . This means that PTGX is currently undervalued and has a potential upside of +11.18% (Margin of Safety).
Is PTGX a buy, sell or hold?
- Strong Buy: 5
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PTGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.7 | 3.6% |
| Analysts Target Price | 80.7 | 3.6% |
| ValueRay Target Price | 101.4 | 30.2% |
PTGX Fundamental Data Overview November 06, 2025
P/E Trailing = 104.7945
P/E Forward = 26.3852
P/S = 22.7515
P/B = 6.0515
Beta = 2.202
Revenue TTM = 209.2m USD
EBIT TTM = 24.0m USD
EBITDA TTM = 25.4m USD
Long Term Debt = 11.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.17m USD (from shortTermDebt, last quarter)
Debt = 11.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -157.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.20b USD (4.76b + Debt 11.3m - CCE 570.5m)
Interest Coverage Ratio = -0.80 (Ebit TTM 24.0m / Interest Expense TTM -29.8m)
FCF Yield = 0.88% (FCF TTM 37.1m / Enterprise Value 4.20b)
FCF Margin = 17.74% (FCF TTM 37.1m / Revenue TTM 209.2m)
Net Margin = 24.88% (Net Income TTM 52.0m / Revenue TTM 209.2m)
Gross Margin = 99.71% ((Revenue TTM 209.2m - Cost of Revenue TTM 604.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 5.85 (Enterprise Value 4.20b / Total Assets 718.0m)
Interest Expense / Debt = 20.36% (Interest Expense 2.30m / Debt 11.3m)
Taxrate = -0.50% (negative due to tax credits) (172.0k / -34.6m)
NOPAT = 24.1m (EBIT 24.0m * (1 - -0.50%)) [negative tax rate / tax credits]
Current Ratio = 16.97 (Total Current Assets 602.5m / Total Current Liabilities 35.5m)
Debt / Equity = 0.02 (Debt 11.3m / totalStockholderEquity, last quarter 668.0m)
Debt / EBITDA = -6.19 (Net Debt -157.3m / EBITDA 25.4m)
Debt / FCF = -4.24 (Net Debt -157.3m / FCF TTM 37.1m)
Total Stockholder Equity = 641.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.25% (Net Income 52.0m / Total Assets 718.0m)
RoE = 8.12% (Net Income TTM 52.0m / Total Stockholder Equity 641.1m)
RoCE = 3.68% (EBIT 24.0m / Capital Employed (Equity 641.1m + L.T.Debt 11.3m))
RoIC = 3.76% (NOPAT 24.1m / Invested Capital 641.1m)
WACC = 14.14% (E(4.76b)/V(4.77b) * Re(14.13%) + D(11.3m)/V(4.77b) * Rd(20.36%) * (1-Tc(-0.00)))
Discount Rate = 14.13% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.38%
[DCF Debug] Terminal Value 49.55% ; FCFE base≈114.6m ; Y1≈78.3m ; Y5≈38.8m
Fair Price DCF = 6.02 (DCF Value 374.4m / Shares Outstanding 62.2m; 5y FCF grow -37.03% → 3.0% )
EPS Correlation: 23.23 | EPS CAGR: 155.6% | SUE: 0.70 | # QB: 0
Revenue Correlation: 64.36 | Revenue CAGR: 158.0% | SUE: -0.05 | # QB: 0
Additional Sources for PTGX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle